Katja Rothfuss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Katja Rothfuss has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
E. F. Stange
Robert‐Bosch‐Hospital, Stuttgart, Germany
3 shared publicationsAleksandra Canevska-Taneska
Cyril and Methodius University, Skopje, North Macedonia
2 shared publicationsAlexander Zoufaly
Department of Medicine IV, Clinic Favoriten and Faculty of Medicine, Sigmund Freud University, Vienna, Austria
2 shared publicationsArmin Papkalla
Centre for Clinical Trials, Medizinische Hochschule, Hannover, Germany
2 shared publicationsBarbara Neuhaus
Centre for Clinical Trials, Medizinische Hochschule, Hannover, Germany
2 shared publications- Björn-Erik Ole Jensen
Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf Heinrich Heine University Düsseldorf Düsseldorf Germany
2 shared publications
Latest Publications
- Open Access
- 20 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1169
Clinical Characteristics and Treatment Strategies in a Cohort of Patients with Tularemia: A Retrospective Multicenter Analysis of 65 Cases in Germany
Background: In recent years, there has been a significant increase in cases of tularemia, a rare zoonotic disease caused by Francisella tularensis, in Europe. Methods: To investigate the epidemiological, clinical, and therapeutic characteristics of tularemia patients in Germany, we performed a retrospective evaluation of tularemia cases treated between 2010 and 2025 at selected treatment centers of the Permanent Working Group of Competence and Treatment Centers for High Consequence Infectious Diseases (STAKOB) at the Robert Koch Institute. Results: A total of 65 patients (median age: 48.5 years; 66.2% male) were identified. Most common manifestation was ulceroglandular (70.7%), followed by oropharyngeal (13.8%), pulmonary (10.8%), oculoglandular (7.7%), typhoidal (4.6%), and meningitic (4.6%). Serological confirmation of the diagnosis was achieved in all patients (90.8% ELISA, 46.2% Western blot). PCR-based direct pathogen detection was successful in 26.2%. Bloodstream infection was detected in 4.6%. Median incubation period was 7 days (IQR: 4–10), with fever being the most common symptom in 96.9% and lymphadenopathy in 46.2%. Median time to recovery was 56 days (IQR: 37–80) in patients diagnosed and treated early (≤3 weeks after symptom onset), compared to 84 days (IQR: 66–182) in patients with late diagnosis (>3 weeks after symptom onset; p = 0.015). Empirical therapy with beta-lactam antibiotics was initiated in 49.2% of cases. Following suspicion of tularemia, 96.9% received recommended treatment with fluoroquinolones, tetracyclines, or aminoglycosides. Conclusions: Delayed diagnosis and inappropriate initial therapy can significantly prolong disease courses and increase morbidity. Early treatment with effective antibiotics, considering the intrinsic beta-lactam resistance of Francisella tularensis, leads to faster recovery.
- 20 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1169
Open AccessClinical Characteristics and Treatment Strategies in a Cohort of Patients with Tularemia: A Retrospective Multicenter Analysis of 65 Cases in Germany
Background: In recent years, there has been a significant increase in cases of tularemia, a rare zoonotic disease caused by Francisella tularensis, in Europe. Methods: To investigate the epidemiological, clinical, and therapeutic characteristics of tularemia patients in Germany, we performed a retrospective evaluation of tularemia cases treated between 2010 and 2025 at selected treatment centers of the Permanent Working Group of Competence and Treatment Centers for High Consequence Infectious Diseases (STAKOB) at the Robert Koch Institute. Results: A total of 65 patients (median age: 48.5 years; 66.2% male) were identified. Most common manifestation was ulceroglandular (70.7%), followed by oropharyngeal (13.8%), pulmonary (10.8%), oculoglandular (7.7%), typhoidal (4.6%), and meningitic (4.6%). Serological confirmation of the diagnosis was achieved in all patients (90.8% ELISA, 46.2% Western blot). PCR-based direct pathogen detection was successful in 26.2%. Bloodstream infection was detected in 4.6%. Median incubation period was 7 days (IQR: 4–10), with fever being the most common symptom in 96.9% and lymphadenopathy in 46.2%. Median time to recovery was 56 days (IQR: 37–80) in patients diagnosed and treated early (≤3 weeks after symptom onset), compared to 84 days (IQR: 66–182) in patients with late diagnosis (>3 weeks after symptom onset; p = 0.015). Empirical therapy with beta-lactam antibiotics was initiated in 49.2% of cases. Following suspicion of tularemia, 96.9% received recommended treatment with fluoroquinolones, tetracyclines, or aminoglycosides. Conclusions: Delayed diagnosis and inappropriate initial therapy can significantly prolong disease courses and increase morbidity. Early treatment with effective antibiotics, considering the intrinsic beta-lactam resistance of Francisella tularensis, leads to faster recovery.
- Open Access
- 1 September 2024
- Published by SAGE Publications in Health Security
- Vol. 22 (1_suppl) , S97-S103
The Role of High-Level Isolation Units in Response to High-Consequence and Emerging Infectious Diseases: Experience of the German STAKOB Network
This case study describes the experience of the German Permanent Working Group of Competence and Treatment Centers for High Consequence Infectious Diseases, known as STAKOB ( Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger ). STAKOB brings together public health authorities (competence centers) and high-level isolation units (treatment centers) to collaborate on the clinical management of high-consequence infectious diseases (HCIDs) and emerging infectious diseases. The network is coordinated by the Robert Koch Institute, Germany’s federal public health institute. The main tasks of STAKOB are to strengthen HCID clinical and public health management and increase expert knowledge on HCID and non-HCID emerging infectious diseases in Germany. STAKOB enables the exchange of knowledge and experiences; development of guidelines on infection prevention and control measures, clinical management, and therapy; and support for the World Health Organization and other outbreak responses internationally. The past years have shown how important the STAKOB network is for Germany—not only in providing critical care for HCID cases but also increasing capacity to support public health and clinical management of emerging infectious disease cases. However, maintaining several high-level isolation units in Germany requires a high commitment of financial, material, and human resources. Due to the rarity of HCID and emerging infectious disease events, maintaining the appropriate level of preparedness and ensuring sufficient investments is an ongoing struggle. Nevertheless, it is essential to have a network ready to react to HCID and non-HCID emerging infectious diseases in times of a changing biosecurity and infectious landscape.
- 1 September 2024
- Published by SAGE Publications in Health Security
- Vol. 22 (1_suppl) , S97-S103
Open AccessThe Role of High-Level Isolation Units in Response to High-Consequence and Emerging Infectious Diseases: Experience of the German STAKOB Network
This case study describes the experience of the German Permanent Working Group of Competence and Treatment Centers for High Consequence Infectious Diseases, known as STAKOB ( Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger ). STAKOB brings together public health authorities (competence centers) and high-level isolation units (treatment centers) to collaborate on the clinical management of high-consequence infectious diseases (HCIDs) and emerging infectious diseases. The network is coordinated by the Robert Koch Institute, Germany’s federal public health institute. The main tasks of STAKOB are to strengthen HCID clinical and public health management and increase expert knowledge on HCID and non-HCID emerging infectious diseases in Germany. STAKOB enables the exchange of knowledge and experiences; development of guidelines on infection prevention and control measures, clinical management, and therapy; and support for the World Health Organization and other outbreak responses internationally. The past years have shown how important the STAKOB network is for Germany—not only in providing critical care for HCID cases but also increasing capacity to support public health and clinical management of emerging infectious disease cases. However, maintaining several high-level isolation units in Germany requires a high commitment of financial, material, and human resources. Due to the rarity of HCID and emerging infectious disease events, maintaining the appropriate level of preparedness and ensuring sufficient investments is an ongoing struggle. Nevertheless, it is essential to have a network ready to react to HCID and non-HCID emerging infectious diseases in times of a changing biosecurity and infectious landscape.
- Open Access
- 16 August 2024
- Published by Springer Nature in Infection
- Vol. 53 (1) , 259-269
Role and benefits of infectious diseases specialists in the COVID-19 pandemic: Multilevel analysis of care provision in German hospitals using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) cohort
Purpose: This study investigates the care provision and the role of infectious disease (ID) specialists during the coronavirus disease-2019 (COVID-19) pandemic. Methods: A survey was conducted at German study sites participating in the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS). Hospitals certified by the German Society of Infectious diseases (DGI) were identified as ID centers. We compared care provision and the involvement of ID specialists between ID and non-ID hospitals. Then we applied a multivariable regression model to analyse how clinical ID care influenced the mortality of COVID-19 patients in the LEOSS cohort. Results: Of the 40 participating hospitals in the study, 35% (14/40) were identified as ID centers. Among those, clinical ID care structures were more commonly established, and ID specialists were always involved in pandemic management and the care of COVID-19 patients. Overall, 68% (27/40) of the hospitals involved ID specialists in the crisis management team, 78% (31/40) in normal inpatient care, and 80% (28/35) in intensive care. Multivariable analysis revealed that COVID-19 patients in ID centers had a lower mortality risk compared to those in non-ID centers (odds ratio: 0.61 (95% CI 0.40–0.93), p = 0.021). Conclusion: ID specialists played a crucial role in pandemic management and inpatient care.
- 16 August 2024
- Published by Springer Nature in Infection
- Vol. 53 (1) , 259-269
Open AccessRole and benefits of infectious diseases specialists in the COVID-19 pandemic: Multilevel analysis of care provision in German hospitals using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) cohort
Purpose: This study investigates the care provision and the role of infectious disease (ID) specialists during the coronavirus disease-2019 (COVID-19) pandemic. Methods: A survey was conducted at German study sites participating in the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS). Hospitals certified by the German Society of Infectious diseases (DGI) were identified as ID centers. We compared care provision and the involvement of ID specialists between ID and non-ID hospitals. Then we applied a multivariable regression model to analyse how clinical ID care influenced the mortality of COVID-19 patients in the LEOSS cohort. Results: Of the 40 participating hospitals in the study, 35% (14/40) were identified as ID centers. Among those, clinical ID care structures were more commonly established, and ID specialists were always involved in pandemic management and the care of COVID-19 patients. Overall, 68% (27/40) of the hospitals involved ID specialists in the crisis management team, 78% (31/40) in normal inpatient care, and 80% (28/35) in intensive care. Multivariable analysis revealed that COVID-19 patients in ID centers had a lower mortality risk compared to those in non-ID centers (odds ratio: 0.61 (95% CI 0.40–0.93), p = 0.021). Conclusion: ID specialists played a crucial role in pandemic management and inpatient care.
- 12 October 2022
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 17 (4) , 472-479
Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease–a Case Series
Pneumocystis jirovecii pneumonia (PJP) is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease (IBD). Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP. PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn’s and Colitis Organization. Clinical data were provided through a case report form. 18 PJP episodes were reported in 17 IBD patients (10 ulcerative colitis and 7 Crohn’s disease). The median age on PJP diagnosis was 55 years (IQR, 40-68 years). Two PJP (11.1%) occurred in patients on triple immunosuppression, 10 patients (55.6%) had double immunosuppressive treatment, 4 patients (22.2%) had monotherapy and 2 PJP occurred in absence of immunosuppressive treatment (one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation). Immunosuppressive therapies included steroids (n=12), thiopurines (n=10), infliximab (n=4), ciclosporin (n=2), methotrexate (n=1) and tacrolimus (n=1). None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulfamethoxazole or atovaquone and an ICU stay was required in 7 cases. Two patients (aged 71 and 32 years) died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others. This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy.
- 12 October 2022
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 17 (4) , 472-479
Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease–a Case Series
Pneumocystis jirovecii pneumonia (PJP) is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease (IBD). Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP. PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn’s and Colitis Organization. Clinical data were provided through a case report form. 18 PJP episodes were reported in 17 IBD patients (10 ulcerative colitis and 7 Crohn’s disease). The median age on PJP diagnosis was 55 years (IQR, 40-68 years). Two PJP (11.1%) occurred in patients on triple immunosuppression, 10 patients (55.6%) had double immunosuppressive treatment, 4 patients (22.2%) had monotherapy and 2 PJP occurred in absence of immunosuppressive treatment (one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation). Immunosuppressive therapies included steroids (n=12), thiopurines (n=10), infliximab (n=4), ciclosporin (n=2), methotrexate (n=1) and tacrolimus (n=1). None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulfamethoxazole or atovaquone and an ICU stay was required in 7 cases. Two patients (aged 71 and 32 years) died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others. This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy.
- 4 September 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (suppl 66)
Impact of Dexamethasone Treatment on COVID-19 Pneumonia Mortality
Background: Treatment strategies for SARS-CoV2 infections changed continuously during the pandemic. Data of the Recovery Trial established dexamethasone as standard of care (SoC) for COVID-19 patients requiring oxygen. Objectives: We assessed the impact of dexamethasone on mortality of patients with COVID-19 pneumonia confirmed by computed tomography scan. Dexamethasone was introduced as SoC at our institution as of August 2020. Methods: We analyzed the mortality of hospitalized patients (n=334) with COVID-19 pneumonia. Group A (no dexamethasone, n=89) consisted of all patients diagnosed before July 31-2020, and Group B (dexamethasone, n=197) comprised all patients between August 01-2020 and February 28-2021. We excluded patients receiving immune or antiviral treatment (n=58). Considered underlying comorbidities were: age>65yo, male sex, obesity, hypertension, diabetes, chronic lung-, heart-, kidney-, liver disease, active malignancy or immunosuppression. Results: Group A (n=89, 38.8% females) patients had a mean age of 64.0±1.52 years and a BMI of 25.8±1.0. The number of comorbidities per patient was 2.00(0-7). The mortality was 19.1%. Group B (n=197, 36.0 % females) patients had a mean age of 70.6±1.09 years and a BMI of 28.7±1.2. The number of comorbidities per patient was 3.00(0-7). The mortality was 26.0%. Conclusion: COVID-19 pneumonia is associated with significant mortality, and characteristics of hospitalized patients changed significantly during the pandemic. The effectiveness of dexamethasone is difficult to assess in this post hoc real-world analysis. We speculate that the number and severity of underlying comorbidities are the main contributing factors to the individual outcome of COVID-19 pneumonia.
- 4 September 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (suppl 66)
Impact of Dexamethasone Treatment on COVID-19 Pneumonia Mortality
Background: Treatment strategies for SARS-CoV2 infections changed continuously during the pandemic. Data of the Recovery Trial established dexamethasone as standard of care (SoC) for COVID-19 patients requiring oxygen. Objectives: We assessed the impact of dexamethasone on mortality of patients with COVID-19 pneumonia confirmed by computed tomography scan. Dexamethasone was introduced as SoC at our institution as of August 2020. Methods: We analyzed the mortality of hospitalized patients (n=334) with COVID-19 pneumonia. Group A (no dexamethasone, n=89) consisted of all patients diagnosed before July 31-2020, and Group B (dexamethasone, n=197) comprised all patients between August 01-2020 and February 28-2021. We excluded patients receiving immune or antiviral treatment (n=58). Considered underlying comorbidities were: age>65yo, male sex, obesity, hypertension, diabetes, chronic lung-, heart-, kidney-, liver disease, active malignancy or immunosuppression. Results: Group A (n=89, 38.8% females) patients had a mean age of 64.0±1.52 years and a BMI of 25.8±1.0. The number of comorbidities per patient was 2.00(0-7). The mortality was 19.1%. Group B (n=197, 36.0 % females) patients had a mean age of 70.6±1.09 years and a BMI of 28.7±1.2. The number of comorbidities per patient was 3.00(0-7). The mortality was 26.0%. Conclusion: COVID-19 pneumonia is associated with significant mortality, and characteristics of hospitalized patients changed significantly during the pandemic. The effectiveness of dexamethasone is difficult to assess in this post hoc real-world analysis. We speculate that the number and severity of underlying comorbidities are the main contributing factors to the individual outcome of COVID-19 pneumonia.
- Open Access
- 31 August 2022
- Published by Elsevier in The Lancet Digital Health
- Vol. 4 (10) , e727-e737
Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study
- 31 August 2022
- Published by Elsevier in The Lancet Digital Health
- Vol. 4 (10) , e727-e737
Open AccessPredictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study
- Open Access
Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a cohort study
Background The SARS-CoV-2 pandemic remains a worldwide challenge. The CRIT-Cov-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression. Following the interim analysis demanded by the German government, the full dataset was analysed to consolidate findings and propose clinical applications. Methods In eight European countries, 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression, receiver operating curve analysis with comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalistion costs standardised across countries. Findings The entry WHO scores were 1-3, 4-5 and 6 in 445 (44·0%), 529 (52·3%), and 38 (3·8%) patients, of whom 119 died and 271 progressed. The standardised odds ratios associated with COV50 for death were 2·44 (95% CI, 2·05-2·92) unadjusted and 1·67 (1·34-2·07) if adjusted for sex, age, body mass index, comorbidities and baseline WHO score, and 1·79 (1·60-2·01) and 1·63 (1·40-1·90), respectively, for disease progression (pInterpretation The urinary proteomic COV50 marker is accurate in predicting adverse COVID-19 outcomes. Even in mild-to-moderate PCR-confirmed infections (WHO scores 1-5), the 0·04 threshold justifies earlier drug treatment, thereby reducing hospitalisation days and costs. Funding German Federal Ministry of Health acting upon a decree from the German Federal Parliament.
Open AccessPredictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a cohort study
Background The SARS-CoV-2 pandemic remains a worldwide challenge. The CRIT-Cov-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression. Following the interim analysis demanded by the German government, the full dataset was analysed to consolidate findings and propose clinical applications. Methods In eight European countries, 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression, receiver operating curve analysis with comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalistion costs standardised across countries. Findings The entry WHO scores were 1-3, 4-5 and 6 in 445 (44·0%), 529 (52·3%), and 38 (3·8%) patients, of whom 119 died and 271 progressed. The standardised odds ratios associated with COV50 for death were 2·44 (95% CI, 2·05-2·92) unadjusted and 1·67 (1·34-2·07) if adjusted for sex, age, body mass index, comorbidities and baseline WHO score, and 1·79 (1·60-2·01) and 1·63 (1·40-1·90), respectively, for disease progression (pInterpretation The urinary proteomic COV50 marker is accurate in predicting adverse COVID-19 outcomes. Even in mild-to-moderate PCR-confirmed infections (WHO scores 1-5), the 0·04 threshold justifies earlier drug treatment, thereby reducing hospitalisation days and costs. Funding German Federal Ministry of Health acting upon a decree from the German Federal Parliament.
- Open Access
- 8 October 2021
- Published by Springer Nature in Infection
- Vol. 50 (2) , 423-436
All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort
Purpose Reported antibiotic use in coronavirus disease 2019 (COVID-19) is far higher than the actual rate of reported bacterial co- and superinfection. A better understanding of antibiotic therapy in COVID-19 is necessary. Methods 6457 SARS-CoV-2-infected cases, documented from March 18, 2020, until February 16, 2021, in the LEOSS cohort were analyzed. As primary endpoint, the correlation between any antibiotic treatment and all-cause mortality/progression to the next more advanced phase of disease was calculated for adult patients in the complicated phase of disease and procalcitonin (PCT) ≤ 0.5 ng/ml. The analysis took the confounders gender, age, and comorbidities into account. Results Three thousand, six hundred twenty-seven cases matched all inclusion criteria for analyses. For the primary endpoint, antibiotic treatment was not correlated with lower all-cause mortality or progression to the next more advanced (critical) phase (n = 996) (both p > 0.05). For the secondary endpoints, patients in the uncomplicated phase (n = 1195), regardless of PCT level, had no lower all-cause mortality and did not progress less to the next more advanced (complicated) phase when treated with antibiotics (p > 0.05). Patients in the complicated phase with PCT > 0.5 ng/ml and antibiotic treatment (n = 286) had a significantly increased all-cause mortality (p = 0.029) but no significantly different probability of progression to the critical phase (p > 0.05). Conclusion In this cohort, antibiotics in SARS-CoV-2-infected patients were not associated with positive effects on all-cause mortality or disease progression. Additional studies are needed. Advice of local antibiotic stewardship- (ABS-) teams and local educational campaigns should be sought to improve rational antibiotic use in COVID-19 patients.
- 8 October 2021
- Published by Springer Nature in Infection
- Vol. 50 (2) , 423-436
Open AccessAll-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort
Purpose Reported antibiotic use in coronavirus disease 2019 (COVID-19) is far higher than the actual rate of reported bacterial co- and superinfection. A better understanding of antibiotic therapy in COVID-19 is necessary. Methods 6457 SARS-CoV-2-infected cases, documented from March 18, 2020, until February 16, 2021, in the LEOSS cohort were analyzed. As primary endpoint, the correlation between any antibiotic treatment and all-cause mortality/progression to the next more advanced phase of disease was calculated for adult patients in the complicated phase of disease and procalcitonin (PCT) ≤ 0.5 ng/ml. The analysis took the confounders gender, age, and comorbidities into account. Results Three thousand, six hundred twenty-seven cases matched all inclusion criteria for analyses. For the primary endpoint, antibiotic treatment was not correlated with lower all-cause mortality or progression to the next more advanced (critical) phase (n = 996) (both p > 0.05). For the secondary endpoints, patients in the uncomplicated phase (n = 1195), regardless of PCT level, had no lower all-cause mortality and did not progress less to the next more advanced (complicated) phase when treated with antibiotics (p > 0.05). Patients in the complicated phase with PCT > 0.5 ng/ml and antibiotic treatment (n = 286) had a significantly increased all-cause mortality (p = 0.029) but no significantly different probability of progression to the critical phase (p > 0.05). Conclusion In this cohort, antibiotics in SARS-CoV-2-infected patients were not associated with positive effects on all-cause mortality or disease progression. Additional studies are needed. Advice of local antibiotic stewardship- (ABS-) teams and local educational campaigns should be sought to improve rational antibiotic use in COVID-19 patients.
- 27 June 2020
- Published by Springer Nature
- p. 147-153
Patient Management before and after EUS/ERCP
- 22 June 2020
- Published by Springer Nature in Gastro-News
- Vol. 7 (3) , 50-53
CED in Zeiten von COVID-19
- 22 June 2020
- Published by Springer Nature in Gastro-News
- Vol. 7 (3) , 50-53
CED in Zeiten von COVID-19